Cited 17 times in
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.